ArticleTranslational psychiatry2026
Intranasal dantrolene nanoparticles inhibit lipopolysaccharide-induced depression and anxiety behavior in mice.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Precision nanomedicine for anxiety: challenges, opportunities, and future directions in targeted drug delivery.Journal of food and drug analysis · 2025Review
- Emerging anti-inflammatory nanosystems targeted to the brain.Nanomedicine (London, England) · 2025Review
- Intranasal Dantrolene Nanoparticles for Treatment of Amyotrophic Lateral Sclerosis as a Disease-Modifying Drug.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
- Update of
Authors and funding
8 authors.
Funding
Abstract
This study investigates the therapeutic effectiveness of intranasal dantrolene nanoparticle pretreatment to inhibit lipopolysaccharide (LPS)-induced pathological inflammation, synapse destruction, and depressive and anxiety behavior in mice. B6SJLF1/J adult mice were pretreated with intranasal dantrolene nanoparticles (dantrolene: 5 mg/kg), daily, Monday to Friday, 5 days per week, for 4 weeks. Afterwards, mice were treated with a single intraperitoneal injection of LPS (5 mg/kg). Behavioral tests for depression and anxiety were performed 24 h after the one-time LPS injection. Biomarkers for pyroptosis-related inflammation cytokine levels (IL-1β and IL-18) in the blood and brain were measured using enzyme-linked immunosorbent assay (ELISA) and immunoblotting, respectively. Changes in primary protein (NLRP3: NLR family pyrin domain containing 3, Caspase-1, N-GSDMD: N-terminal protein gasdermin D) and synapse protein-related (PSD-95 and synaptin-1) activation of inflammatory pyroptosis in mouse brains were measured using immunoblotting. Results indicated that intranasal dantrolene nanoparticle treatment robustly inhibited LPS-induced increases in depressive and anxiety behavior, LPS-induced pathological elevation of IL-1β and IL-18 levels in the blood and brain, and LPS-induced activation of pyroptosis. Furthermore, intranasal dantrolene nanoparticles significantly inhibited decreased PSD-95 and synaptin-1 levels. Intranasal dantrolene nanoparticles have demonstrated neuroprotective effects against inflammation-mediated depression and anxiety behaviors and should be studied further as a future effective drug treatment of major depressive or anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.